Altitude Group PLC (ALT)
Summary
ALT Chart
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolution and fibrosis improvement, but competition from semaglutide, resmetirom, and others remains intense. ALT's near-term catalyst is the Phase 2 AUD data, with potential for partnership if results demonstrate differentiation in heavy drinking reduction and liver outcomes.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
Altitude Group PLC (ALT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Altitude Group PLC ever had a stock split?
Altitude Group PLC Profile
| Biotechnology Industry | Healthcare Sector | Jerome Benedict Durso CEO | LSE Exchange | G0370K100 CUSIP |
| US Country | 57 Employees | 14 Sep 2018 Last Dividend | 14 Sep 2018 Last Split | 6 Oct 2005 IPO Date |
Overview
Altimmune, Inc., originally established under the name Vaxin Inc., is a biopharmaceutical company that has been at the forefront of clinical stage development since its foundation in 1997. With a strategic focus geared towards addressing obesity and liver diseases, the company has become a key player in the field. Having rebranded to Altimmune, Inc. in September 2015, the organization continues to advance its mission from its headquarters in Gaithersburg, Maryland. By leveraging its expertise in biopharmaceuticals, Altimmune is dedicated to bringing innovative treatments to patients battling these complex health issues.
Products and Services
- Pemvidutide
Pemvidutide stands as Altimmune's leading product candidate, a pioneering GLP-1/glucagon dual receptor agonist tailored for obesity treatment. This novel therapy is currently undergoing a Phase 2 clinical trial, showcasing its potential in combatting obesity and the metabolic dysfunctions associated with steatohepatitis. By targeting two critical pathways involved in metabolism, Pemvidutide exemplifies Altimmune's commitment to addressing the growing global obesity epidemic with science-driven solutions.
- HepTcell
Another significant advancement from Altimmune is HepTcell, an innovative immunotherapeutic aimed at treating chronic hepatitis B virus (HBV) infection. Currently in a Phase 2 clinical trial, HepTcell embodies Altimmune's strategic effort to combat viral liver diseases by harnessing the body's immune response. Through this approach, HepTcell offers hope to patients suffering from chronic HBV, showcasing Altimmune's dedication to tackling infectious diseases with cutting-edge biopharmaceutical technologies.
